Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

DIVE INTO DIALYSIS: NxStage Aims To Transform Home Hemodialysis Into $2bn Market

This article was originally published in Clinica

Executive Summary

For the second part of Clinica’s three-part special series on the dialysis market, Reed Miller talked to the CEO of NxStage Medical, a Massachusetts-based company that markets the NxStage System One, which the firm touts as the only “truly portable” hemodialysis system FDA-cleared for home hemodialysis and home nocturnal hemodialysis. As the company is set to face competition for home hemodialysis customers from upstarts like Quanta, profiled in part 1 of this series, and giants like Fresenius Medical Care, the subject of part 3, NxStage is planning to use home hemodialysis as a “beachhead” to invade other, more lucrative markets